NYSE:BMYPharmaceuticals
Is Bristol Myers (BMY) Undervalued After Its Recent Share Price Rebound?
Bristol-Myers Squibb (BMY) has quietly staged a comeback, with the stock up about 16% over the past month and 18% in the past 3 months, even as revenue dipped last year.
See our latest analysis for Bristol-Myers Squibb.
That rebound comes after a tougher stretch, with the share price still posting a year-to-date share price return of negative 4.5 percent and a 1-year total shareholder return of negative 1.3 percent, suggesting sentiment is improving but the longer-term picture is still...